| Objective To observe the therapeutic effect of liraglutide on male T2DM patients with osteoporosis (OP). Methods All the cases were selected from T2DM patients who were hospitalized in our department in 2018 and 2019, including 68 patients with osteoporosis (OP group) and 60 patients without osteoporosis(T2DM group). The course of disease, age, glycosylated hemoglobin, blood lipids (TC, TG, HDL, LDL), bone metabolism indicators (25 hydroxyvitamin D,parathyroid hormone, osteocalcin, TP1NP, osteocalcin, etc. Then compare the bone metabolism and bone mineral density of patients in OP group before treatment, after treatment for 12 weeks and after stopping treatment for 12 weeks. Results (1) BMI, HbA1c, TC, TG, LDL, PTH, OC, TP1NP and β-CTX in OP group were higher than those in T2DM group, while BMD was lower. (2) After taking liraglutide for 12 weeks, BMI, HbA1c, LDL, TG, TP1NP and β-CTX decreased, while 25-OH-D and BMD increased in male T2DM patients with osteoporosis (OP). At the end of the study, when liraglutide was stopped for 12 weeks, the TP1NP and HbA1c of patients in OP group increased compared with those before stopping, while BMD showed a downward trend. (3) Compared with the control group, there was no significant difference in HbA1c in the OP group after 12 weeks of treatment, but the levels of LDL and TP1NP decreased, while the levels of 25-hydroxyvitamin D and BMD increased. The difference of BMI between the OP group and T2DM group decreased, and the degree of obesity improved. Conclusion Liraglutide not only has a particularly good hypoglycemic effect, but also is beneficial to weight control and blood lipid regulation, and can improve bone density. Besides, its bone improvement effect is independent of that brought by blood glucose and blood lipid control, and It can be used as the first choice and recommended drug for diabetic patients with osteoporosis, which can not only improve blood sugar and blood lipid, manage body weight, but also increase bone density. |